Statera Biopharma sells rights to addiction-treatment drug, still faces delisting from Nasdaq

FORT COLLINS — For the second time in less than a month, Statera Biopharma Inc. (Nasdaq: STAB) has sold its rights to produce a drug as it seeks to shore up its financial position. 

The life-sciences company sold its rights to naltrexone, an addiction-treatment drug designed to reduce cravings for alcohol and opioids, to Florida company Immune Therapeutics Inc. The transaction is contingent on the completion of a definitive agreement.

For the rights to naltrexone, Statera will receive $2 million in cash and 5% of the outstanding Immune Therapeutics common stock. Statera will also receive payments for achievement of revenue-based milestones, new…